Skip to content
15
Societies
SSH
Categories
Session

Oral presentations Hemostasis, transfusion medicine, vascular, laboratory medicine, benign hematology

- , Kairo 1-2

Schedule Slot

Oral presentations Hemostasis, transfusion medicine, vascular, laboratory medicine, benign hematology

15
Societies
SSH
Categories
Session

Oral presentations Hemostasis, transfusion medicine, vascular, laboratory medicine, benign hematology

- , Kairo 1-2
  1. Is dual targeting of FXII and Gas6 a good strategy to prevent thrombosis with no risks of bleeding?

    Presentation time:
    10 min
    Discussion time:
    4 min
  2. Effectiveness of emicizumab under real-world conditions in patients of all ages with hemophilia A with and without FVIII inhibitors: Fourth interim analysis of the non-interventional study EMIIL

    Presentation time:
    10 min
    Discussion time:
    4 min
  3. Temporal phosphoproteomics reveals key regulators of procoagulant COAT platelet generation

    Presentation time:
    10 min
    Discussion time:
    4 min
  4. Modulation of protein S benefits joint integrity and bone health in hemophilia A

    Presentation time:
    10 min
    Discussion time:
    4 min
  5. NET formation contributes to clinical relapses but not ADAMTS13 biomarker relapses in immune-mediated thrombotic thrombocytopenic purpura (iTTP)

    Presentation time:
    10 min
    Discussion time:
    4 min
  6. Clinical impact of pathogen-reduced platelet concentrates stored for up to 7 days in routine use in patients receiving allogeneic haematopoietic stem cell transplantation in Switzerland

    Presentation time:
    10 min
    Discussion time:
    4 min